In 2025, the oncology community has seen the successful deployment of AI-driven platforms like CURATE.AI, which create "Digital Twins" of patients to optimize chemotherapy dosing. Traditionally, dosing is based on Body Surface Area (BSA), which often leads to over-treatment or under-treatment. The new AI models analyze real-time biomarkers (such as CEA or CA125) and previous drug responses to recommend doses that can be 20% lower than standard protocols while maintaining identical efficacy.

This shift toward "Dynamic Dosing" is particularly critical in palliative care, where the goal is to maximize quality of life by minimizing side effects. Technical data on AI-driven patient stratification and the reduction of "Trial-and-Error" in drug selection are detailed in the Chemotherapy Market technology reports. As AI tools gain FDA clearance for primary treatment planning, "Personalized Oncology" is moving from genomic mapping to the real-time adjustment of every infusion.